DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Study Overview
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors.
Study Description
The purpose of this study is to evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
Additional Information
Participants will not be paid for their participation.
- IRB Number: 1703616209 (S1609)
- Research Study Identifier: TX7674
- Principal Investigator: Kathy Miller, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
